Turnstone Biologics Announces FDA Clearance of IND for TIDAL-01, a Next-Generation TIL Therapy for Solid Tumors

SAN DIEGO–(BUSINESS WIRE)– #SelectedTILs–Turnstone’s innovative approach with TIDAL-01 focuses on selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs).
Click here to view original post